Harki to Serve as Co-Investigator and Deputy Director of Medicinal Chemistry and DMPK
The University of Minnesota has received $66 million from the National Institute of Allergy and Infectious Diseases (NIAID) to establish a center to develop antiviral drugs for pandemic-level viruses, including SARS-CoV-2.
The Midwest Antiviral Drug Discovery (AViDD) Center is part of a network of nine national centers established by NIAID in response to the public health emergency caused by COVID-19.
The hub of the Center is located in Minnesota with two-thirds of the scientists located in the broader Midwest. Dr. Daniel Harki, Northrop Professor in the College of Pharmacy’s Department of Medicinal Chemistry, serves as co-Investigator and Deputy Director of the Medicinal Chemistry and Drug Metabolism and Pharmacokinetics (DMPK) Core.
College of Pharmacy, email@example.com
Founded in 1892, the University of Minnesota, College of Pharmacy is the only pharmacy school in Minnesota, with campuses in the Twin Cities and in Duluth. The College of Pharmacy improves health through innovative education, pioneering research and interdisciplinary practice development that attends to the diverse needs of the people of Minnesota and the world.